Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study


Sage Therapeutics Inc SAGE and Biogen Inc BIIB said zuranolone combined with a standard of care antidepressant met the primary goal of showing rapid and significant reduction in depressive symptoms in a late-stage study.

  • The drug, zuranolone, also met the study's secondary goal of showing an improvement in symptoms when administered with a standard of care antidepressant, compared to a combination of placebo and antidepressants over two weeks.
  • Related: Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients.
  • Sage plans to start submitting data for U.S. approval of zuranolone for major depressive disorder on a rolling basis early this year and is aiming to complete the application by the second half of the year.
  • Zuranolone 50 mg co-initiated with a standard of care antidepressant was generally well-tolerated, with most TEAEs reported as mild or moderate and no new safety signals identified.
  • Price Action: SAGE shares are down 16% at $36.27, BIIB stock is down 0.58% at $216.10 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsdepressionPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!